HER2-Targeted Combo Boosts PFS in Advanced Breast Cancer

1 source1 article First seen 1 day ago Updated 1 day ago United States Truth score 38

Save Like Comments Compare coverage

Summary

A phase 3 trial evaluates the efficacy and safety of anbenitamab plus albumin-bound docetaxel vs docetaxel, trastuzumab, and pertuzumab in patients with HER2-positive advanced breast cancer.

Description from Medscape.

Who is covering this

Medscape Center Factuality: Mostly factual US 1 day ago
HER2-Targeted Combo Boosts PFS in Advanced Breast Cancer
A phase 3 trial evaluates the efficacy and safety of anbenitamab plus albumin-bound docetaxel vs docetaxel, trastuzumab, and pertuzumab in patients with HER2-positive advanced breast cancer.

Comments

Comments need JavaScript.

Truth score

38/100Weakly supported

Independent outlets: 1
Source reliability: 65/100
Sides of the spectrum covering it: 1/3
Propaganda risk: 0/100

How well the story is corroborated by independent, reliable outlets across the spectrum. Not a fact-check of each claim. How the truth score works

Coverage by lean

Centre 100%100%

Left: 0
Centre: 1
Right: 0
Not rated: 0

How lean is counted

Source quality

Average reliability: 65/100 (Mostly factual)
Low-credibility outlets: 0%
State media: 0%
Opinion pieces: 0%

Where ratings come from

Where the coverage comes from

United States1

Filter the stories

Sources Ratings and details

HER2-Targeted Combo Boosts PFS in Advanced Breast Cancer

Summary

Who is covering this

Comments